IconOVir Bio Announces Preclinical Proof-of-Concept Data for Proprietary Mutations Designed to Improve Selectivity of Novel Oncolytic Viruses, Including Lead Product Candidate ICVB-1042

Combined E1A and E4-ORF6/7 mutations demonstrate high degree of tumor selectivity in lead product candidate ICVB-1042 (formerly IOV-1042) IND filing for ICVB-1042 expected 1H 2022 Data published online in ASCO 2021 Annual Meeting Proceedings SAN DIEGO, CA., May 20, 2021 – IconOVir Bio, Inc. (IconOVir), a preclinical-stage biotechnology company pioneering the next generation of oncolytic […]